Shakeel Modak

8.3k total citations
160 papers, 4.7k citations indexed

About

Shakeel Modak is a scholar working on Neurology, Molecular Biology and Oncology. According to data from OpenAlex, Shakeel Modak has authored 160 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Neurology, 52 papers in Molecular Biology and 51 papers in Oncology. Recurrent topics in Shakeel Modak's work include Neuroblastoma Research and Treatments (127 papers), Cancer therapeutics and mechanisms (38 papers) and Cancer, Hypoxia, and Metabolism (35 papers). Shakeel Modak is often cited by papers focused on Neuroblastoma Research and Treatments (127 papers), Cancer therapeutics and mechanisms (38 papers) and Cancer, Hypoxia, and Metabolism (35 papers). Shakeel Modak collaborates with scholars based in United States, Spain and India. Shakeel Modak's co-authors include Nai‐Kong V. Cheung, Brian H. Kushner, Kim Kramer, Michael P. LaQuaglia, Irene Y. Cheung, Suzanne L. Wolden, Neeta Pandit‐Taskar, Ellen M. Basu, Stephen S. Roberts and Sameer Farouk Sait and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Shakeel Modak

150 papers receiving 4.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Shakeel Modak 2.6k 1.7k 1.5k 869 827 160 4.7k
Jaume Mora 1.4k 0.5× 3.1k 1.9× 1.2k 0.8× 1.0k 1.2× 715 0.9× 216 5.5k
Julie R. Park 4.9k 1.9× 3.3k 2.0× 3.6k 2.3× 2.1k 2.4× 372 0.4× 185 8.5k
Tali Siegal 1.5k 0.6× 1.0k 0.6× 1.3k 0.8× 504 0.6× 1.3k 1.5× 121 5.2k
Annunziato Mangiola 1.1k 0.4× 2.2k 1.3× 556 0.4× 1.8k 2.1× 438 0.5× 117 5.2k
Karen Leroy 531 0.2× 1.3k 0.8× 2.0k 1.3× 760 0.9× 766 0.9× 126 4.8k
Dietrich von Schweinitz 1.6k 0.6× 3.2k 1.9× 1.5k 1.0× 1.3k 1.5× 754 0.9× 189 6.8k
Penelope Brock 1.2k 0.5× 1.4k 0.8× 1.6k 1.1× 775 0.9× 782 0.9× 93 4.9k
A D Pearson 1.1k 0.4× 1.1k 0.7× 686 0.4× 525 0.6× 377 0.5× 69 3.0k
Antonio Silvani 403 0.2× 944 0.6× 931 0.6× 398 0.5× 765 0.9× 182 3.3k
Vincent A. Memoli 333 0.1× 1.9k 1.1× 1.6k 1.1× 1.5k 1.8× 960 1.2× 124 4.8k

Countries citing papers authored by Shakeel Modak

Since Specialization
Citations

This map shows the geographic impact of Shakeel Modak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shakeel Modak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shakeel Modak more than expected).

Fields of papers citing papers by Shakeel Modak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shakeel Modak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shakeel Modak. The network helps show where Shakeel Modak may publish in the future.

Co-authorship network of co-authors of Shakeel Modak

This figure shows the co-authorship network connecting the top 25 collaborators of Shakeel Modak. A scholar is included among the top collaborators of Shakeel Modak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shakeel Modak. Shakeel Modak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kushner, Brian H., Shakeel Modak, Audrey Mauguen, et al.. (2025). A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission. Clinical Cancer Research. 31(10). 1877–1884. 1 indexed citations
2.
Jackson, Christina, Shakeel Modak, Michael P. LaQuaglia, et al.. (2024). Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results from a Prospective Clinical Trial. International Journal of Radiation Oncology*Biology*Physics. 120(2). S49–S49.
3.
Pandit‐Taskar, Neeta, et al.. (2024). Safety observations in neuroblastoma patients undergoing 18F-mFBG PET. Nuclear Medicine Communications. 46(3). 245–247. 2 indexed citations
4.
Kushner, Brian H., Audrey Mauguen, Ellen M. Basu, et al.. (2024). N9: Pilot study of novel shortened induction for high-risk neuroblastoma.. Journal of Clinical Oncology. 42(16_suppl). 10052–10052.
5.
Kushner, Brian H., et al.. (2023). Anaplastic Lymphoma Kinase Inhibitors for Therapy of Neuroblastoma in Adults. JCO Precision Oncology. 7(7). e2300138–e2300138. 4 indexed citations
6.
Mora, Jaume, et al.. (2023). GM‐CSF, G‐CSF or no cytokine therapy with anti‐GD2 immunotherapy for high‐risk neuroblastoma. International Journal of Cancer. 154(8). 1340–1364. 8 indexed citations
7.
Kushner, Brian H., Shakeel Modak, Michael P. LaQuaglia, et al.. (2023). Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy.. Journal of Clinical Oncology. 41(16_suppl). 10037–10037. 1 indexed citations
8.
Kushner, Brian H., Shakeel Modak, Ellen M. Basu, et al.. (2021). Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN‐amplified neuroblastoma. Pediatric Blood & Cancer. 68(10). e29265–e29265. 8 indexed citations
9.
Modak, Shakeel, Pat Zanzonico, Milan Grkovski, et al.. (2020). B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. Journal of Clinical Oncology. 38(36). 4283–4291. 53 indexed citations
10.
Mathias, Melissa, Michael V. Ortiz, Kay See Tan, et al.. (2019). Local Anesthesia With General Anesthesia for Pediatric Bone Marrow Procedures. PEDIATRICS. 144(2). 3 indexed citations
11.
Modak, Shakeel, Jean-Benoît Le Luduec, Irene Y. Cheung, et al.. (2018). Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. OncoImmunology. 7(8). e1461305–e1461305. 70 indexed citations
12.
Geoerger, Birgit, Franck Bourdeaut, Steven G. DuBois, et al.. (2017). A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research. 23(10). 2433–2441. 121 indexed citations
13.
Cheung, Irene Y., Brian H. Kushner, Shakeel Modak, et al.. (2017). Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. OncoImmunology. 6(11). e1358331–e1358331. 28 indexed citations
14.
Mukhopadhyay, A., Arup K. Mandal, Shrawan Kumar Singh, Ravimohan S. Mavuduru, & Shakeel Modak. (2017). The evaluation and outcome of a new intravesical BCG protocol for non-muscle invasive bladder cancer in a tertiary care center In India. Annals of Oncology. 28. x83–x83. 1 indexed citations
15.
Modak, Shakeel, et al.. (2015). Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma. Journal of Pediatric Hematology/Oncology. 37(6). e381–e383. 7 indexed citations
16.
Cheung, Nai‐Kong V., Irene Y. Cheung, Kim Kramer, et al.. (2014). Key role for myeloid cells: Phase II results of anti‐GD2 antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblastoma. International Journal of Cancer. 135(9). 2199–2205. 70 indexed citations
17.
Kushner, Brian H., Amy Budnick, Kim Kramer, Shakeel Modak, & Nai‐Kong V. Cheung. (2006). Ototoxicity from high‐dose use of platinum compounds in patients with neuroblastoma. Cancer. 107(2). 417–422. 109 indexed citations
18.
Modak, Shakeel, et al.. (2005). Radioimmunotargeting of Human Rhabdomyosarcoma Using Monoclonal Antibody 8H9. Cancer Biotherapy and Radiopharmaceuticals. 20(5). 534–546. 29 indexed citations
19.
Lawrence, Andrew D., et al.. (2004). Molecular Phylogeny in 3-D. Current Issues in Molecular Biology. 6(2). 189–200. 2 indexed citations
20.
Cheung, Nai‐Kong V., Hong-Fen Guo, Shakeel Modak, & Irene Y. Cheung. (2002). Anti-Idiotypic Antibody as the Surrogate Antigen for Cloning scFv and its Fusion Proteins. PubMed. 21(6). 433–443. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jaume Mora Breakdown of academic impact, for papers by Julie R. Park Breakdown of academic impact, for papers by Tali Siegal Breakdown of academic impact, for papers by Annunziato Mangiola Breakdown of academic impact, for papers by Karen Leroy Breakdown of academic impact, for papers by Dietrich von Schweinitz Breakdown of academic impact, for papers by Penelope Brock Breakdown of academic impact, for papers by A D Pearson Breakdown of academic impact, for papers by Antonio Silvani Breakdown of academic impact, for papers by Vincent A. Memoli
Rankless by CCL
2026